Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells

Journal of Cellular Biochemistry

Volumn 89, Issue 1, 2003, Pages 1-5

  Chaudhary, Lala R ^a   Hruska, Keith A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Apoptosis; Cell survival; Curcumin; DU 145; LNCaP; PC 3; Prostate cancer

Indexed keywords

CURCUMIN; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; SERUM;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CULTURE MEDIA; CURCUMIN; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; PLATELET-DERIVED GROWTH FACTOR; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0037404397     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10495     Document Type: Article

References (27)

1. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. 2002. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: Its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23:143-150.
2. Bastola DR, Pahwa GS, Lin MF, Cheng PW. 2002. Down-regulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Mol Cell Biochem 236:75-81.
3. Chaudhary LR, Hruska KA. 2001. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, FGF-2 in osteoblastic cells. J Cell Biochem 81:304-311.
4. Chen Y-R, Tan T-H. 1998. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17:173-178.
5. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13:2905-2927.
6. Denis L, Morton MS, Griffiths K. 1999. Diet and its preventive role in prostatic disease. Eur Urol 35:377-387.
7. Dorai T, Gehani N, Katz A. 2000. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 4:1-6.
8. Dorai T, Cao Y-C, Dorai B, Buttyan R, Katz AE. 2001. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. The Prostate 47:293-303.
9. Greenlee RT, Murray T, Bolden S, Wingo PA. 2000. Cancer statistics. Cancer J Clin 50:7-33.
10. Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. 2002. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141-6145.
11. Hill MM, Hemings BA. 2002. Inhibition of protein kinase B/Akt: Implications for cancer therapy. Pharmacol Ther 93:243-251.
12. Huang T-S, Lee S-C, Lin J-K. 1991. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 88:5292-5296.
13. Huang M-T, Newmark HL, Frenkel K. 1997. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem 27:26-34.
14. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC. 1999. Progress in cancer chemoprevention. Ann NY Acad Sci 889:1-13.
15. Koeneman KS, Yeung F, Chung LWK. 1999. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. The Prostate 39:246-261.
16. Kreis W. 1995. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 13:296-312.
17. Liu J-Y, Lin S-J, Lin J-K. 1993. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14:857-861.
18. Lu Y-P, Chang RL, Huang M-T, Conney AH. 1993. Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 14:293-297.
19. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:7597-7609.
20. Plummer SM, Holloway KA, Manson MM, Munks RJL, Kaptein A, Farrow S, Howells L. 1999. Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 18:6013-6020.
21. Rao CV, Simi B, Reddy BS. 1993. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14:2219-2225.
22. Russell PJ, Bennett S, Stricker P. 1998. Growth factor involvement in progression of prostate cancer. Clin Chem 44:705-723.
23. Satoskar RR, Shah SJ, Shenoy SG. 1986. Evaluation of the anti-inflammatory properties of curcumin (diferuloylmethane) in patients with post-operative inflammation. Int J Clin Pharm Ther Toxicol 24:651-654.
24. Singh S, Aggarwal BB. 1995. Activation of transcription factor NF-κB is suppressed by curcumin (Diferulolylmethane). J Biol Chem 270:24995-25000.
25. Srimal RC, Dhawan BN. 1973. Pharmacology of diferuloylmethane (curcumin) - a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25:447-452.
26. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlung B, Hansen KL, Vinson VL, Gumpper KL. 1997. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225.
27. Tsugawa K, Jones MK, Sugimachi K, Sarfeh IJ, Tarnwawski AS. 2002. Biological role of phosphatase PTEN in cancer and tissue injury healing. Front Biosci 7:e245-e251.